Table 3. Univariate and multivariate analyses of 185 women with 2018 FIGO stage IIIC cervical cancer with regard to OS.
| Characteristic | Cases (5-year OS [%]) | Univariate analyses | Multivariate analyses | |||
|---|---|---|---|---|---|---|
| p-value | HR | 95% CI | p-value | |||
| Age (yr) | 0.96 | |||||
| ≥50 | 24/97 (67.8) | |||||
| <50 | 18/88 (73.6) | |||||
| Histopathology | 0.02 | 1.84 | 0.99–4.32 | 0.05 | ||
| SCC | 27/146 (76.5) | |||||
| AC or ASC | 15/39 (52.6) | |||||
| Cervical stromal invasion | 0.92 | |||||
| <2/3 | 6/24 (72.2) | |||||
| ≥2/3 | 36/161 (70.3) | |||||
| Parametrial invasion | 0.01 | 1.11 | 0.53–2.32 | 0.77 | ||
| Absent | 24/137 (76.2) | |||||
| Present | 18/48 (56.3) | |||||
| Primary tumor size (cm) | 0.04 | 1.52 | 0.76–3.02 | 0.22 | ||
| <4.0 | 14/80 (77.0) | |||||
| ≥4.0 | 28/105 (65.2) | |||||
| Vaginal involvement | 0.002 | 2.09 | 1.05–4.13 | 0.03 | ||
| Absent | 25/143 (76.5) | |||||
| Present | 17/42 (51.7) | |||||
| LVSI | 0.20 | |||||
| Absent | 1/9 (87.5) | |||||
| Present | 41/176 (69.6) | |||||
| Positive surgical margins | 0.30 | |||||
| No | 32/154 (71.8) | |||||
| Yes | 10/31 (50.5) | |||||
| Ovarian metastasis | 0.35 | |||||
| Absent | 36/170 (72.4) | |||||
| Present | 4/8 (42.9) | |||||
| BSO/USO not performed | 2/7 (71.4) | |||||
| Uterine corpus invasion | 0.81 | |||||
| Absent | 29/138 (73.2) | |||||
| Present | 13/47 (66.2) | |||||
| FIGO stage | 0.26 | |||||
| IIIC1 | 28/138 (74.0) | |||||
| IIIC2 | 14/47 (60.4) | |||||
| LNR | 0.007 | 1.95 | 1.01–3.77 | 0.04 | ||
| <0.05 | 13/88 (78.2) | |||||
| ≥0.05 | 29/97 (48.4) | |||||
FIGO, International Federation of Gynecology and Obstetrics; OS, overall survival; HR, hazards ratio; CI, confidence interval; SCC, squamous cell carcinoma; AC, adenocarcinoma; ASC, adenosquamous carcinoma; LVSI, lymphovascular space invasion; LN, lymph node; BSO, bilateral salphingo-oopherectomy; USO, unilateral salphingo-oopherectomy; LNR, lymph node ratio.